Data from Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74<sup>+</sup> B-cell Malignancies

Abstract

<div>Abstract<p><b>Purpose:</b> Corticosteroids are widely used for the treatment of B-cell malignancies, including non–Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia; however, this class of drug is associated with undesirable off-target effects. Herein, we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74<sup>+</sup> B-cell malignancies and explored its effect against the disease.</p><p><b>Experimental Design:</b> The targeting efficiency of milatuzumab-targeted liposomes to CD74<sup>+</sup> cells was evaluated <i>in vitro</i>. The effect of CD74-targeted liposomal dexamethasone was compared with free dexamethasone in primary CLL cells and cell lines <i>in vitro</i>. The therapeutic efficacy of CD74-targeted liposomal dexamethasone was evaluated in a Raji-severe combined immunodeficient (SCID) xenograft model <i>in vivo</i>.</p><p><b>Results:</b> Milatuzumab-targeted liposomes promoted selective incorporation of carrier molecules into transformed CD74-positive B cells as compared with CD74-negative T-cells. The CD74-dexamethasone–targeted liposomes (CD74-IL-DEX) promoted and increased killing in CD74-positive tumor cells and primary CLL cells. Furthermore, the targeted drug liposomes showed enhanced therapeutic efficacy against a CD74-positive B-cell model as compared with free, or non-targeted, liposomal dexamethasone in SCID mice engrafted with Raji cells <i>in vivo</i>.</p><p><b>Conclusions:</b> These studies provide evidence and support for a potential use of CD74-targeted liposomal dexamethasone as a new therapy for B-cell malignancies. <i>Clin Cancer Res; 19(2); 347–56. ©2012 AACR</i>.</p></div>